CA2933556A1 - Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof - Google Patents

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof Download PDF

Info

Publication number
CA2933556A1
CA2933556A1 CA2933556A CA2933556A CA2933556A1 CA 2933556 A1 CA2933556 A1 CA 2933556A1 CA 2933556 A CA2933556 A CA 2933556A CA 2933556 A CA2933556 A CA 2933556A CA 2933556 A1 CA2933556 A1 CA 2933556A1
Authority
CA
Canada
Prior art keywords
crystalline form
compound
alpha
dihydroxy
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2933556A
Other languages
English (en)
French (fr)
Inventor
Ke Wu
Gyorgy Ambrus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2933556A1 publication Critical patent/CA2933556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2933556A 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof Abandoned CA2933556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
US61/915,575 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
CA2933556A1 true CA2933556A1 (en) 2015-06-18

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2933556A Abandoned CA2933556A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Country Status (16)

Country Link
US (2) US9353079B2 (enExample)
EP (1) EP3080096A1 (enExample)
JP (2) JP2016539994A (enExample)
KR (1) KR20160097310A (enExample)
CN (1) CN105814033B (enExample)
AU (1) AU2014361794B2 (enExample)
BR (1) BR112016013594A8 (enExample)
CA (1) CA2933556A1 (enExample)
CL (2) CL2016001448A1 (enExample)
IL (2) IL245917B (enExample)
MX (1) MX2016007717A (enExample)
RU (1) RU2730520C2 (enExample)
SA (1) SA516371307B1 (enExample)
SG (2) SG11201604787SA (enExample)
UA (1) UA121108C2 (enExample)
WO (1) WO2015089475A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10765629B2 (en) * 2017-07-25 2020-09-08 Allergan, Inc. Solid complex, preparations and uses thereof
US20230338194A1 (en) * 2020-01-29 2023-10-26 Kci Licensing, Inc. Mutliple fluid pathway connector with foam supports

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO143741C (no) * 1972-07-13 1981-04-08 Pfizer Analogifremgangsmaate for fremstilling av fysiologisk aktive prostaglandinforbindelser av e- og f-serien
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE69613693T2 (de) * 1995-05-18 2002-05-16 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes

Also Published As

Publication number Publication date
RU2730520C2 (ru) 2020-08-24
US9353079B2 (en) 2016-05-31
CN105814033A (zh) 2016-07-27
UA121108C2 (uk) 2020-04-10
AU2014361794A1 (en) 2016-06-16
AU2014361794B2 (en) 2019-04-04
CN105814033B (zh) 2019-10-25
CL2016001448A1 (es) 2017-03-03
IL245917A0 (en) 2016-08-02
EP3080096A1 (en) 2016-10-19
SG11201604787SA (en) 2016-07-28
US20150166504A1 (en) 2015-06-18
IL283810A (en) 2021-07-29
BR112016013594A8 (pt) 2020-05-19
JP2016539994A (ja) 2016-12-22
US20170087163A1 (en) 2017-03-30
SA516371307B1 (ar) 2018-10-04
KR20160097310A (ko) 2016-08-17
BR112016013594A2 (enExample) 2017-08-08
IL245917B (en) 2021-06-30
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
MX2016007717A (es) 2016-09-09
CL2019000471A1 (es) 2019-07-12
JP2020073513A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
EP1072266B1 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
JP2017128605A (ja) 抗ウイルス化合物の固体形態
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
KR0162637B1 (ko) 단백질 키나아제 c 억제제로서 유용한 신규 퀴놀릴옥사졸-2-온
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
CA3157657A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
EP2528908B1 (en) Therapeutic agents for treatment of ocular hypertension
JP2005519117A (ja) キノリン誘導体
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
CN1225093A (zh) 苯并[g]喹啉衍生物
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
HK1227389B (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
JPWO2006082820A1 (ja) 性器ヘルペス治療剤
HK1178524B (en) Therapeutic agents for treatment of ocular hypertension
HK1178524A (en) Therapeutic agents for treatment of ocular hypertension
FR2761065A1 (fr) Derives de n-(arginyle)benzenesulfonamide, leur preparation et leur application en therapeutique
HUP9902404A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(2H)-indol-2-on (ziprazidon) mezilát-dihidrát sói, a vegyületek előállitása és dopamin D2 antagonistaként történő alkalmazása

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230306